Literature DB >> 19918162

Deaths with transdermal fentanyl patches.

Mary I Jumbelic1.   

Abstract

Fentanyl is a potent Schedule II narcotic analgesic recommended for use in the management of unremitting pain not controlled by morphine or other opiate/opioid drugs. The danger inherent to fentanyl is its potency (greater than 50-100 times that of morphine) and rapidity of action, causing respiratory depression within minutes of administration. Advisories have been issued on a state and national level to health care providers and through manufacturers' package inserts for patients. Still, as will be demonstrated in this case review, the use of only a single transdermal patch taken as prescribed for the first time can prove fatal. A drug that requires such extensive warnings-that if unheeded lead to death because of its narrow therapeutic/toxic window, should have strict criteria and limited outpatient use. Initial medical observation and documentation for determining tolerance might be required before issuing a prescription. There has been a rise in the popularity of this drug evidenced by increased deaths among drug abusers and more prescriptions written. In the year 2006, the Center for Forensic Sciences in Onondaga County had 8 cases where fentanyl was considered the cause of death, often with other drugs detected in therapeutic concentrations. This number was a marked increase from the 1 to 2 cases occurring annually from 2002 to 2005. All of these 2006 overdoses because of fentanyl involved the transdermal formulation. The investigative data, blood and liver fentanyl levels, and autopsy findings will be presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19918162     DOI: 10.1097/PAF.0b013e31818738b8

Source DB:  PubMed          Journal:  Am J Forensic Med Pathol        ISSN: 0195-7910            Impact factor:   0.921


  23 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

2.  Time to pain relief after immediate-release morphine in episodic pain: the TIME study.

Authors:  Claudio Lo Presti; Alessandro Roscetti; Davide Muriess; Massimo Mammucari
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Dependence and addiction during chronic opioid therapy.

Authors:  David N Juurlink; Irfan A Dhalla
Journal:  J Med Toxicol       Date:  2012-12

4.  U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.

Authors:  Aishwarya Vijay; Taeho Greg Rhee; Joseph S Ross
Journal:  Prev Med       Date:  2019-03-17       Impact factor: 4.018

5.  Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-07       Impact factor: 2.007

6.  Reliability of postmortem fentanyl concentrations in determining the cause of death.

Authors:  James R Gill; Peter T Lin; Lewis Nelson
Journal:  J Med Toxicol       Date:  2013-03

Review 7.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

Review 8.  [Limits of pain treatment: medical and judicial aspects].

Authors:  M Zenz; R Rissing-van Saan
Journal:  Schmerz       Date:  2011-08       Impact factor: 1.107

9.  Assisted suicide by fentanyl intoxication due to excessive transdermal application.

Authors:  Martin Juebner; Mathias Fietzke; Justus Beike; Markus A Rothschild; Katja Bender
Journal:  Int J Legal Med       Date:  2014-02-28       Impact factor: 2.686

10.  Polymer excipients enable sustained drug release in low pH from mechanically strong inorganic geopolymers.

Authors:  Erik Jämstorp; Tejaswi Yarra; Bing Cai; Håkan Engqvist; Susanne Bredenberg; Maria Strømme
Journal:  Results Pharma Sci       Date:  2012-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.